4.25 tirzepatide Flex-Dose 4 mL Injectable 10 mg/mL Weight Loss Results at 25

Peyronie's disease: 2 g/day for 3 months reduced pain and slowed disease progression (Biagiotti 2001) [7][66]

An early study 25 addressed this question by genotyping 9 SNPs associated with serum UA in a series of PD and matched control subjects to obtain a polygenic risk score (PRS) for low UA

Concentration(s) Common formulations:- **PT-141 Injectable:** 10 mg/mL reconstituted solution- **Sermorelin Injectable:** 3 mg/mL, 6 mg/mL, 9 mg/mL- **GHK-Cu Topical:** 0.1% 3%- **NAD+ Injectable:** 100 mg/mL 500 mg/mL- **Oral Troche (PT-141, Sermorelin, NAD+):** 0.5-2 mg per dose Maximum Dosage (Day, Wk) Recommended maximum doses:- **PT-141:** 1.75 mg subcutaneous per dose, max 2 doses per week- **Sermorelin:** 200-500 mcg subcutaneous per dose, daily- **GHK-Cu:** Apply 1-2 times daily- **NAD+:** 50-500 mg subcutaneous per dose, 1-3x per week Contraindications Pregnancy, breastfeeding, active cancer, history of pituitary tumors, cardiovascular disease (for PT-141), history of melanoma (for GHK-Cu), uncontrolled hypertension, or hypersensitivity to any of the compounds

Continuous minimally-invasive alcohol monitoring using microneedle sensor arrays

Prices typically range from approximately $1,000 to $2,000 per month without insurance